Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride … Read more
Beijing Beilu Pharmaceutical (300016) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.032x
Based on the latest financial reports, Beijing Beilu Pharmaceutical (300016) has a cash flow conversion efficiency ratio of 0.032x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥74.66 Million) by net assets (CN¥2.37 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Beijing Beilu Pharmaceutical - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Beijing Beilu Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Beijing Beilu Pharmaceutical Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing Beilu Pharmaceutical ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ardagh Metal Packaging SA
NYSE:AMBP
|
-0.542x |
|
Sturm Ruger & Company Inc
NYSE:RGR
|
0.046x |
|
Guangdong Cellwise Microelectronics Co. Ltd.
SHG:688325
|
N/A |
|
Boozt AB (publ)
PINK:BZTAF
|
0.379x |
|
Daewoong Pharma
KO:069620
|
0.057x |
|
AP (Thailand) Public Company Limited
BK:AP-R
|
0.063x |
|
Societe LDC SA
PA:LOUP
|
0.091x |
|
Xizi Clean Energy Equipment Manufacturing Co Ltd
SHE:002534
|
0.030x |
Annual Cash Flow Conversion Efficiency for Beijing Beilu Pharmaceutical (2006–2024)
The table below shows the annual cash flow conversion efficiency of Beijing Beilu Pharmaceutical from 2006 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.83 Billion | CN¥163.02 Million | 0.089x | +172.27% |
| 2023-12-31 | CN¥1.79 Billion | CN¥58.46 Million | 0.033x | -50.75% |
| 2022-12-31 | CN¥1.92 Billion | CN¥127.81 Million | 0.066x | +27.42% |
| 2021-12-31 | CN¥2.08 Billion | CN¥108.73 Million | 0.052x | -43.93% |
| 2020-12-31 | CN¥1.89 Billion | CN¥176.00 Million | 0.093x | -13.95% |
| 2019-12-31 | CN¥1.45 Billion | CN¥156.81 Million | 0.108x | -25.83% |
| 2018-12-31 | CN¥1.21 Billion | CN¥175.75 Million | 0.146x | +7.54% |
| 2017-12-31 | CN¥1.07 Billion | CN¥144.92 Million | 0.136x | +60.46% |
| 2016-12-31 | CN¥901.69 Million | CN¥76.17 Million | 0.084x | -2.56% |
| 2015-12-31 | CN¥932.63 Million | CN¥80.85 Million | 0.087x | +37.19% |
| 2014-12-31 | CN¥666.33 Million | CN¥42.11 Million | 0.063x | -14.55% |
| 2013-12-31 | CN¥559.38 Million | CN¥41.37 Million | 0.074x | +69.54% |
| 2012-12-31 | CN¥523.96 Million | CN¥22.86 Million | 0.044x | -53.12% |
| 2011-12-31 | CN¥491.47 Million | CN¥45.73 Million | 0.093x | +15.98% |
| 2010-12-31 | CN¥467.62 Million | CN¥37.51 Million | 0.080x | -39.92% |
| 2009-12-31 | CN¥433.71 Million | CN¥57.91 Million | 0.134x | +473.67% |
| 2008-12-31 | CN¥133.23 Million | CN¥-4.76 Million | -0.036x | -126.30% |
| 2007-12-31 | CN¥90.33 Million | CN¥12.28 Million | 0.136x | -50.49% |
| 2006-12-31 | CN¥71.59 Million | CN¥19.65 Million | 0.274x | -- |